1. Home
  2. Directory
  3. Alabama
  4. Birmingham
  5. Ophthalmology
  6. NPI Profile
  7. Prescriptions 1689324329

AMIRA RUTH ABBAS MD
Prescription History 1689324329
Ophthalmology in Birmingham, AL

NPI Status: Active since March 25, 2022

Contact Information

2208 UNIVERSITY BLVD STE 101
BIRMINGHAM, AL
ZIP 35233
Phone: (205) 933-2625
Fax: (205) 558-2567

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for AMIRA RUTH ABBAS MD, an active Ophthalmology specialist practicing in Birmingham, AL. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 71 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 32 claims alone.

Medication Index

B
L
P
R
No matching medications currently found on file.

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 12
30-Day Fills 16.8
Days Supply 504
AL State Average Benchmarks
Peer Average Claims65.0
Peer Average 30-Day Fills113.1
Peer Average Days Supply3,255
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.5% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $197.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.47

State Avg Cost Per Claim

$52.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 32
30-Day Fills 51.3
Days Supply 1,447
AL State Average Benchmarks
Peer Average Claims169.0
Peer Average 30-Day Fills289.9
Peer Average Days Supply8,250
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.1% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,012.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.64

State Avg Cost Per Claim

$23.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.2
Days Supply 256
AL State Average Benchmarks
Peer Average Claims124.0
Peer Average 30-Day Fills155.2
Peer Average Days Supply3,905
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 89.5% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $548.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.16

State Avg Cost Per Claim

$54.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Rocklatan

Generic Formulation: Netarsudil Mesylat/LatanoprostSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 14
30-Day Fills 21.0
Days Supply 546
AL State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills59.0
Peer Average Days Supply1,600
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.2% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,294.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$521.03

State Avg Cost Per Claim

$447.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Netarsudil/latanoprost is used to treat high pressure inside the eye due to certain eye conditions (such as open-angle glaucoma, ocular hypertension). Lowering high pressure inside the eye can help prevent vision loss or blindness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like AMIRA RUTH ABBAS MD provides transparency into local medical care patterns within Birmingham, AL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.